使用progestin(PPOS, duphaston 20mg/d) vs GnRH antagonist 應用於試管誘導排卵之LH抑制

使用progestin(PPOS, duphaston 20mg/d) vs  GnRH antagonist 應用於試管誘導排卵之LH抑制 
 
PPOS 組和 GnRH antagonist的整倍體率相當(分別為 12.5% 和 16.0%,P > 0.05)。
 
兩組FET在每次移植的妊娠試驗陽性率、臨床懷孕率、流產率、子宮外孕率或活產率方面均無顯著差異。
 
Comparison of the euploidy rate  following progestin-primed vs GnRHantagonist protocol
Euploidy rate was comparable between the PPOS and antagonist group (12.5% vs. 16.0% respectively, P > 0.05). 
No significant differences were observed between the two groups in positive pregnancy test, clinical pregnancy, miscarriage, ectopic pregnancy, or live birth rates per transfer in the first frozen embryo transfer cycles.
Both PPOS and antagonist protocols had similar euploidy rates in PGT-A cycles.
 

Variables

PPOS group (n = 120)

Antagonist group (n = 120)

P-value

Starting dose of FSH (IU)

225.0 (225.0-225.0)

225.0 (225.0-225.0)

0.134

Total dosage of FSH (IU)

1800.0 (1575.0-2025.0)

1800.0 (1575.0-2212.5)

0.010

Duration of stimulation (days)

8.0 (7.0-8.8)

8.0 (7.0–9.0)

0.053

Serum estradiol level on trigger day (pg/ml)

1870.5 (912.7-2940.1)

1061.3 (592.0-2614.1)

0.007

Serum LH level on trigger day (IU/l)

4.3 (2.7–5.9)

2.4 (1.6–3.6)

0.000

Serum progesterone level on trigger day (ng/ml)

0.9 (0.6–1.2)

0.8 (0.6–1.2)

0.588

Premature ovulation (%)

0.8 (1/120)

0.8 (1/120)

1

No. of retrieved oocytes (n)

6.0 (3.0–10.0)

5.0 (3.0–10.0)

0.914

No. of mature occytes (n)

4.5 (2.0–8.0)

4.0 (3.0–9.0)

0.980

No. of oocytes fertilized (n)

3.0 (2.0–7.0)

3.0 (2.0–6.0)

0.728

Fertilization rate (%)

94.4 (75.0-100)

92.9 (75.0-100)

0.746

Cleavage rate (%)

100 (100–100)

100 (100–100)

0.648

No. of blastocysts formation (n)

1.5 (0–3.0)

1.0 (0–3.0)

0.422

Blastocysts formation rate (%)

59.4 (33.3–100)

50.0 (33.3–80)

0.299

Total No. of euploid blastocysts

93

97

 

No. of euploid blastocysts (n)

0 (0–1.0)

0 (0–1.0)

0.995

Euploid blastocysts rate per injected oocyte (%)

12.5 (0–25.0)

16.0 (0-27.7)

0.477

Euploid blastocysts rate per woman (%)

33.3 (0-66.7)

50.0 (0-66.7)

0.459

No. of cycles with no blastocyst for biopsy (%)

27.5 (33/120)

30.0 (36/120)

0.669

No. of cycles with no euploid blastocysts for transfer (%)

52.5 (63/120)

55.0 (66/120)

0.698

 

PPOS group (n = 53)

Antagonist group (n = 47)

P-value

Endometrial preparation, n (%)

   

0.995

Natural cycles

1.9 (1/53)

2.0% (1/47)

 

Clomid-induced

11.5 (6/53)

10.0 (5/47)

 

Hormonal cycles

83.0 (44/53)

91.5 (43/47)

 

Endometrial thickness (day of trigger) (mm)

10.0 (8.6–11.0)

9.1 (8.5–10.4)

0.600

hCG test positive rate (%)

66.0 (35/53)

70.2 (33/47)

0.655

Clinical pregnancy rate (%)

58.5 (31/53)

59.6 (28/47)

0.912

Clinical miscarriage rate (%)

9.7 (3/31)

17.9 (5/28)

0.359

Ectopic pregnancy rate (%)

0 (0/35)

0 (0/33)

0

Live birth rate (%)

52.8 (28/53)

48.9 (23/47)

0.359

 

TOP